Company „Biocentras“ – among leading innovators in the EuropaBio’s Most Innovative Biotech SME Award 2011

22.11.2011

EuropaBio has announced top five finalists for its 2011 Most Innovative EU Biotech SME Award. 

The winner became company Prosensa, which was awarded a prize of €10,000 as well as two year’s free membership of EuropaBio, was revealed at a high-level event in the European Parliament on November 8th. It included keynote speeches on the past and future of the biotech industry by G. Steven Burrill, Founder and CEO of Burrill & Company as well as an overview of the EU’s innovation-related initiatives in favour of SMEs by Daniel Calleja-Crespo, EU Commission Deputy Director DG Industry & Entrepreneurship and special SME envoy. 

As occurred last year, event took attention of large audience of EU policy makers, industrial leaders, scientists, venture capitalists and media, as Europe’s top scientists and their companies present their solutions to global challenges such as degenerative medical conditions, environmental challenges and meeting the needs of an ever increasing and ageing global population.

The finalists, who presented their innovative discoveries at the award ceremony included: 

AiCuris GmbH & Co. KG (Germany), a company focused on developing new medicines that fight against infectious diseases with a high impact on society, such as HIV, Human Cytomegalovirus, Herpes, Hepatitis and resistant bacterial infections in hospitals; 

Biocentras (Lithuania), who work to solve environmental challenges such as land and water pollution as well as focusing on improved recycling and waste management; 

Cardio3 Biosciences (Belgium), working on the discovery, development and commercialisation of regenerative and protective therapies for heart diseases;

Prosensa (The Netherlands), an SME whose technology is at the forefront of developing a treatment for Duchenne Muscular Dystrophy (DMD) - a lethal childhood rare disease; and 

to-BBB (The Netherlands), who have discovered a new technology to enhance drug delivery across the bloodbrain barrier to treat medical conditions such as brain cancer, Alzheimer’s disease and multiple sclerosis.

To be shorlisted among five top European biotevhnologies companies is high achievement of Lithuanian company „Biocentras“.

 

To view the original article published by Mokslo Naujienos, please click here